Johnson & Johnson (J&J; NYSE: JNJ) announced receipt of Fast Track designation from the US FDA for nipocalimab, an investigational anti-neonatal Fc receptor (FcRn) monoclonal antibody, for the treatment of adults with systemic lupus erythematosus (SLE). This is the fifth FDA Fast Track designation for nipocalimab, which Johnson & Johnson acquired through its USD 6.5 billion purchase of Momenta Pharmaceuticals in October 2020.
FDA Fast Track designation is available to therapies intended to treat serious conditions where evidence suggests the drug may address an unmet medical need. The procedural benefits include more frequent interactions with the agency during development, eligibility for rolling submission of a Biologics License Application (BLA), and potential qualification for Accelerated Approval or Priority Review at the time of filing.
The designation rests on data from the Phase II JASMINE study (NCT04882878), a 52-week, randomized, double-blind, placebo-controlled, dose-ranging trial enrolling 228 adults with active SLE. According to Johnson & Johnson, the study met its primary endpoint and multiple secondary and exploratory endpoints, demonstrating reduction in lupus disease activity and steroid-sparing potential. Nipocalimab is the only FcRn blocker to have shown reduction in SLE disease activity in a controlled Phase II setting. Following these results, Johnson & Johnson initiated enrollment in the Phase III GARDENIA study (NCT07438496) of adults with active SLE.
Nipocalimab functions by binding FcRn with high affinity, blocking IgG recycling and thereby reducing circulating pathogenic immunoglobulin G (IgG) autoantibodies while preserving other immune functions. J&J is developing the molecule across rheumatologic, rare autoantibody, and maternal-fetal indications. Active or completed trials include Phase III studies in generalized myasthenia gravis (gMG), where FDA granted Priority Review in Q4 2024, and in fetal and neonatal alloimmune thrombocytopenia (FNAIT). Nipocalimab also holds Breakthrough Therapy designations for hemolytic disease of the fetus and newborn (HDFN) and Sjögren’s disease.
Research context
SLE is a chronic autoimmune disease affecting an estimated 3 to 5 million people worldwide, with disproportionate prevalence among women of reproductive age. The disease drives inflammation across multiple organ systems, including the kidneys, skin, joints, and central nervous system, and carries a risk of irreversible organ damage compounded by long-term glucocorticoid dependence. Only two biologic therapies have received FDA approval for SLE: belimumab (GSK, approved 2011), a B-lymphocyte stimulator inhibitor, and anifrolumab (AstraZeneca, branded Saphnelo, approved 2021), a type I interferon receptor antibody. No novel molecular entity for SLE has been approved since anifrolumab.
The FcRn target class is crowded. Argenx markets efgartigimod (Vyvgart) for gMG and is studying it in lupus nephritis in the Phase II/III ALKIVIA trial (NCT05523570). UCB’s rozanolixizumab and Immunovant’s batoclimab are both in Phase III for gMG and other IgG-mediated conditions, though neither has disclosed an active SLE program. Nipocalimab differs from efgartigimod in modality: it is a full-length monoclonal antibody rather than an engineered Fc fragment, and J&J characterizes it as “immunoselective”, a term denoting its design to lower pathogenic IgG without broadly suppressing other immunoglobulin classes or complement-dependent functions. Whether this translates into a differentiated clinical profile in SLE remains to be established in Phase III data.